" class="no-js "lang="en-US"> Rohit Nambisan - Medtech Alert
Saturday, June 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Rohit Nambisan

Rohit Nambisan

About Rohit Nambisan

Rohit Nambisan is a product leader with management experience across multiple healthcare technology domains, including Big Pharma, medical devices, personalized medicine, Health IT, health data and analytics, and AI. Prior to leading Lokavant, Rohit was most recently the Head of Digital Product at Roivant and the Head of Product at Prognos.

Related Story

Artificial Intelligence

 H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials | Pharmtech Focus

H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials

August 4 2022

H1, the connecting force for global HCP, clinical, scientific, and research information, and Lokavant, the […]